Comparative study of hypoglycemic effects of oral vildagliptin and voglibose on fasting blood sugar level in albino rats

Mukesh Kumar, Mukesh Kumar, Akash Chandra, Uma Shankar Prasad Keshri, Rajiv Kumar


Background: Diabetes mellitus is a metabolic disorder in which there is increased blood sugar level, glycosuria, dyslipidemia and sometimes ketonemia occurs. Increased blood sugar level leads to characteristic symptoms such as polydipsia, polyurea, blurring of vision, polyphagia and weight loss.

Methods: Healthy male Wister rats weighing between 150-250 gm were taken. Total 2 groups A and B were prepared and each group contains 6 animals. Group A was administered voglibose as 0.6 mg/70 kg body weight. Group B was administered vildagliptin as 100 mg/70 kg body weight. Diabetes was induced in group A and B by administration of 120 mg/kg body weight of nicotinamide and 60 mg/kg body weight of streptozocin intraperitoneally. Streptozocin was administered after 15-20 minutes of administration of nicotinamide. After 72 hours of streptozotocin injection, fasting blood glucose level was determined and induction of diabetes was confirmed. The fasting blood samples were collected from all the groups on further days 7, 14, 21 and 28 day to determine the glucose level by glucometer. 

Results: The decline in fasting blood sugar level by voglibose was 36.4% on day 7, 40.2% on day 14, 43.94% on day 21 and 46.4% on day 28. The reduction in Fasting blood sugar level by vildagliptin was 49% on day 7, 52.25% on day 14 and 54% on day 21 and 28. Thus in group B rats, decline was maximal on day 7 and little fall was recorded on subsequent days. It suggests good efficacy as vildagliptin normalized the blood glucose level effectively.  

Conclusions: Vildagliptin was found significantly more effective in lowering fasting blood glucose level than voglibose.


Glycosuria, Dyslipidemia, Ketonemia, Charcot joint, Polydipsia, Polyurea, Polyphasia

Full Text:



Powers AC. Diabetes mellitus: In. Harrison’s principles of internal medicine. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson J et al. The Mcgraw Hill Company. United States of America. 18th ed. 2012;386-94.

Alberti KGMM, Zimmer PZ. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus, Provisional Report of a WHO Consultation. Diabetic medi. 1998;15:539-53.

Power AC, D’Alessio D. Endocrine Pancreas and pharmacotherapy of diabetes mellitus and hypoglycaemia: In. Goodmann and Gilmann’s the pharmacological basis of therapeutics. 2012;43:1261-2.

Gobal prevalence of diabetes: estimates for the year 200 and projections for 2030. Diabetic Care. 2004;27(5):1047-53.

Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;5:S1-85.

Chan JC, Malik V, Jia W. Diabetes in Asia: Epidemiology, risk factor and pathophysiology. JAMA. 2009;301:2129-32.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.

Powers AC. Diabetes Mellitus, In: Fauci AS. Editor, Harrisons Principles of Internal Medicine, 17th Ed. New Delhi: McGraw Hill. 2008;2275-304.

Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 Diabetes: Preclinical biology and mechanism of action. Diabetes Care. 2007;30:1335-43.

Ahren B, Schmitz O. GLP-1 receptor agonist and DPP-4 inhibitors in the treatment of type-2 diabetes. Horm Metal Res. 2004;36:867-76.

Mari A, Sallas M, He YL, Watson C, Ligueros-Saylan M, Dunning BE et al. Vildagliptin, a dipeptidyl peptidase IV inhibitor, improves model-assessed ß-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888-894.

Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther. 2009;329(2):669-76.

Saito N, Sakai H, Suzuki S, Sekihara H, Yajima Y. Effect of an alphglucosidase inhibitor in combination with sulfonylurea. J Int Med Res. 1998;26(5):219-32.

Byrd J, Minor D, Elsayed R, Marshall G. DPP-4 inhibitors and angioedema: a cause for concern? Ann Allergy Asthma Immunol. 2011;106:436-8.